Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence

, , , &
Journal of Law, Medicine and Ethics 47 (3):381-387 (2019)
  Copy   BIBTEX

Abstract

The FDA's new table of surrogate endpoints used for drug approvals is an important step forward for overseeing the use of biomarkers in clinical trials. Nevertheless, we present several ways in which the table can be improved.

Categories

Keywords

Reprint years

DOI

10.1177/1073110519876167

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,386

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation.Audrey D. Zhang & Joseph S. Ross - 2019 - Journal of Law, Medicine and Ethics 47 (3):393-395.
Cochrane's Linked Data Project: How it Can Advance our Understanding of Surrogate Endpoints.Chris Mavergames, Deirdre Beecher, Lorne A. Becker, A. Last & A. Ali - 2019 - Journal of Law, Medicine and Ethics 47 (3):374-380.
Toward a Jurisprudence of Drug Regulation.Matthew Herder - 2014 - Journal of Law, Medicine and Ethics 42 (2):244-262.
A call to restructure the drug development process: Government over-regulation and non-innovative late stage (phase III) clinical trials are major obstacles to advances in health care.Thomas C. Jones - 2005 - Science and Engineering Ethics 11 (4):575-587.
Altruistic surrogacy: the necessary objectification of surrogate mothers.M. M. Tieu - 2009 - Journal of Medical Ethics 35 (3):171-175.
Challenges and Opportunities for Biomarker Validation.Spencer Phillips Hey, Elvira D'Andrea, Emily H. Jung, Frazer Tessema, Jing Luo, Bishal Gyawali & Aaron S. Kesselheim - 2019 - Journal of Law, Medicine and Ethics 47 (3):357-361.
Race, Pharmacogenomics, and Marketing: Putting BiDil in Context.Jonathan Kahn - 2006 - American Journal of Bioethics 6 (5):W1-W5.
Drug regulation in the philippines.Allan Grand A. Sobrepena - unknown
Analysis of Bioethical Problems Regarding Surrogate Conception in Japan.Masayuki Kodama - 2011 - Eubios Journal of Asian and International Bioethics 21 (1-2):34-36.
If Health Care Advertising Is a Problem, FDA-Style Regulation Is Not the Solution.Vanessa Carbonell - 2014 - American Journal of Bioethics 14 (3):46-47.
The Ethics of Commercial Surrogate Mothering: A Response to Casey Humbyrd.Peter Omonzejele - 2011 - Human Reproduction and Genetic Ethics 17 (1):110-121.
Generalized bullous fixed drug eruption treated with cyclosporine.Malviya Neeta, Cyrus Nika, Vandergriff Travis & Mauskar Melissa - unknown
Off-Label Drug Use as a Consent and Health Regulation Issue in New Zealand.Rebecca Julia Cook - 2015 - Journal of Bioethical Inquiry 12 (2):251-258.
Drug Laws, Ethics, and History.Adam Greif - 2019 - Filozofia 74 (2):95 - 110.
"Through Her I Too Shall Bear a Child": Birth Surrogates in Jewish Law.Elie Spitz - 1996 - Journal of Religious Ethics 24 (1):65-97.

Analytics

Added to PP
2019-09-28

Downloads
9 (#1,228,347)

6 months
5 (#638,139)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Spencer Hey
Harvard University

Citations of this work

Biomarker Validation: Context and Complexities.Lisa M. McShane - 2019 - Journal of Law, Medicine and Ethics 47 (3):388-392.

Add more citations

References found in this work

No references found.

Add more references